Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Novel Biomarkers of Renal Function in Type II Diabetes: Effective SGLT2 Inhibition
FY 2017-18
Summary
Diabetes is one of the most prevalent diseases today, with 422 million patients diagnosed globally in 2014; 90% of whom have Type 2 Diabetes Mellitus (T2DM). This complex metabolic disorder is the leading cause of kidney failure, and a growing global health epidemic. Diabetic kidney disease (DKD), previously termed diabetic nephropathy, is a principle microvascular complication of T2DM characterized by a progressive decline in kidney function. Although current practice has helped slow down disease progression, 50% of patients with T2DM still suffer from chronic kidney disease and are at high risk for end stage renal disease. Sodium glucose cotransporter-2 (SGLT2) inhibitors, approved by Health Canada in 2014, are the first class of diabetic medications that have demonstrated a beneficial and protective effect on kidney and cardiovascular health in patients with T2DM. By inhibiting glucose reabsorption in the kidneys, SGLT2 inhibitors allow glucose to be excreted through urine, thereby regulating blood glucose levels. The SGLT2 inhibitor, empagliflozin, has shown to improve kidney function and reduce the incidence of DKD by 39% in patients with T2DM. By analyzing novel and traditional biomarkers of kidney function, the proposed research aims to shed light on the molecular changes in the kidneys after treatment with empagliflozin in patients with T2DM. These innovative targets may allow for early detection of kidney damage, improved risk stratification, and more timely treatment of patients with T2DM. The proposed research will develop the current understanding of the encouraging benefits of empagliflozin, its clinical use, and potential in primary and secondary prevention of kidney disease in T2DM.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386363
Name
Opingari Erika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Biomarkers of Renal Function in Type II Diabetes: Effective SGLT2 Inhibition
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiovascular Disease; Diabetic Kidney Disease; Diagnostic Markers; Disease Pathophysiology; Multiplex Assays; Novel Biomarkers; Secondary Prevention; Type 2 Diabetes
Abstract
Diabetes is one of the most prevalent diseases today, with 422 million patients diagnosed globally in 2014; 90% of whom have Type 2 Diabetes Mellitus (T2DM). This complex metabolic disorder is the leading cause of kidney failure, and a growing global health epidemic. Diabetic kidney disease (DKD), previously termed diabetic nephropathy, is a principle microvascular complication of T2DM characterized by a progressive decline in kidney function. Although current practice has helped slow down disease progression, 50% of patients with T2DM still suffer from chronic kidney disease and are at high risk for end stage renal disease. Sodium glucose cotransporter-2 (SGLT2) inhibitors, approved by Health Canada in 2014, are the first class of diabetic medications that have demonstrated a beneficial and protective effect on kidney and cardiovascular health in patients with T2DM. By inhibiting glucose reabsorption in the kidneys, SGLT2 inhibitors allow glucose to be excreted through urine, thereby regulating blood glucose levels. The SGLT2 inhibitor, empagliflozin, has shown to improve kidney function and reduce the incidence of DKD by 39% in patients with T2DM. By analyzing novel and traditional biomarkers of kidney function, the proposed research aims to shed light on the molecular changes in the kidneys after treatment with empagliflozin in patients with T2DM. These innovative targets may allow for early detection of kidney damage, improved risk stratification, and more timely treatment of patients with T2DM. The proposed research will develop the current understanding of the encouraging benefits of empagliflozin, its clinical use, and potential in primary and secondary prevention of kidney disease in T2DM.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Opingari, Erika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~